DOI: 10.1186/1741-7015-7-7. Recent developments in Alzheimer's disease therapeutics

Recent developments in Alzheimer's disease therapeutics

10.1186/1741-7015-7-7

Crossref journal-article

Springer Science and Business Media LLC

BMC Medicine (297)

Bibliography

Rafii, M. S., & Aisen, P. S. (2009). Recent developments in Alzheimerâs disease therapeutics. BMC Medicine, 7(1).

Authors 2

Michael S Rafii (first)
Paul S Aisen (additional)

References 19 Referenced 130

Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126/science.1072994. (10.1126/science.1072994) / Science by J Hardy (2002)
Gervais F: GAG mimetics: potential to modify underlying disease process in AD. Neurobiol Aging. 2004, 25: S11-12. / Neurobiol Aging by F Gervais (2004)
Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D: A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006, 67: 1757-1763. 10.1212/01.wnl.0000244346.08950.64. (10.1212/01.wnl.0000244346.08950.64) / Neurology by PS Aisen (2006)
Relkin NR: Current state of immunotherapy for Alzheimer's disease. CNS Spectr. 2008, 13 (Suppl 16): 39-41. (10.1017/S1092852900027061) / CNS Spectr by NR Relkin (2008)
DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM: Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002, 295: 2264-2267. 10.1126/science.1067568. (10.1126/science.1067568) / Science by RB DeMattos (2002)
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64: 1553-1562. 10.1212/01.WNL.0000159740.16984.3C. (10.1212/01.WNL.0000159740.16984.3C) / Neurology by S Gilman (2005)
Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD: RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med. 2007, 7: 735-742. 10.2174/156652407783220741. (10.2174/156652407783220741) / Curr Mol Med by X Chen (2007)
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE: NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003, 112: 440-449. (10.1172/JCI18162) / J Clin Invest by JL Eriksen (2003)
Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA: Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008, 7: 483-493. 10.1016/S1474-4422(08)70090-5. (10.1016/S1474-4422(08)70090-5) / Lancet Neurol by GK Wilcock (2008)
Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJl: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008, 65: 1031-1038. 10.1001/archneur.65.8.1031. (10.1001/archneur.65.8.1031) / Arch Neurol by AS Fleisher (2008)
Wolfe MS: Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics. 2008, 5: 391-398. 10.1016/j.nurt.2008.05.010. (10.1016/j.nurt.2008.05.010) / Neurotherapeutics by MS Wolfe (2008)
Ghosh AK, Gemma S, Tang J: beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics. 2008, 5: 399-408. 10.1016/j.nurt.2008.05.007. (10.1016/j.nurt.2008.05.007) / Neurotherapeutics by AK Ghosh (2008)
McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE: Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem. 2000, 275: 18495-18502. 10.1074/jbc.M906994199. (10.1074/jbc.M906994199) / J Biol Chem by J McLaurin (2000)
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW: Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008, 7: 779-786. 10.1016/S1474-4422(08)70167-4. (10.1016/S1474-4422(08)70167-4) / Lancet Neurol by L Lannfelt (2008)
Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA. 1996, 93: 11213-11218. 10.1073/pnas.93.20.11213. (10.1073/pnas.93.20.11213) / Proc Natl Acad Sci USA by CM Wischik (1996)
Gura T: Hope in Alzheimer's fight emerges from unexpected places. Nat Med. 2008, 14: 894-10.1038/nm0908-894. (10.1038/nm0908-894) / Nat Med by T Gura (2008)
Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L: NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005, 11: 353-368. (10.1111/j.1527-3458.2005.tb00053.x) / CNS Drug Rev by I Gozes (2005)
Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS: A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008, 325: 146-153. 10.1124/jpet.107.130526. (10.1124/jpet.107.130526) / J Pharmacol Exp Ther by Y Matsuoka (2008)
Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008, 372: 207-215. 10.1016/S0140-6736(08)61074-0. (10.1016/S0140-6736(08)61074-0) / Lancet by RS Doody (2008)

Dates

Type	When
Created	16 years, 6 months ago (Feb. 27, 2009, 9:16 a.m.)
Deposited	8 years, 2 months ago (June 18, 2017, 9:12 a.m.)
Indexed	2 days, 17 hours ago (Sept. 3, 2025, 6:49 a.m.)
Issued	16 years, 6 months ago (Feb. 19, 2009)
Published	16 years, 6 months ago (Feb. 19, 2009)
Published Online	16 years, 6 months ago (Feb. 19, 2009)
Published Print	15 years, 9 months ago (Dec. 1, 2009)

Funders 0

None

BibTeX

@article{Rafii_2009, title={Recent developments in Alzheimer’s disease therapeutics}, volume={7}, ISSN={1741-7015}, url={http://dx.doi.org/10.1186/1741-7015-7-7}, DOI={10.1186/1741-7015-7-7}, number={1}, journal={BMC Medicine}, publisher={Springer Science and Business Media LLC}, author={Rafii, Michael S and Aisen, Paul S}, year={2009}, month=feb }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        9,
        3
      ]
    ],
    "date-time": "2025-09-03T10:49:56Z",
    "timestamp": 1756896596960
  },
  "reference-count": 19,
  "publisher": "Springer Science and Business Media LLC",
  "issue": "1",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2009,
            2,
            19
          ]
        ],
        "date-time": "2009-02-19T00:00:00Z",
        "timestamp": 1235001600000
      },
      "content-version": "unspecified",
      "delay-in-days": 0,
      "URL": "http://www.springer.com/tdm"
    }
  ],
  "content-domain": {
    "domain": [],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2009,
        12
      ]
    ]
  },
  "DOI": "10.1186/1741-7015-7-7",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2009,
        2,
        27
      ]
    ],
    "date-time": "2009-02-27T14:16:06Z",
    "timestamp": 1235744166000
  },
  "source": "Crossref",
  "is-referenced-by-count": 130,
  "title": "Recent developments in Alzheimer's disease therapeutics",
  "prefix": "10.1186",
  "volume": "7",
  "author": [
    {
      "given": "Michael S",
      "family": "Rafii",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Paul S",
      "family": "Aisen",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "297",
  "published-online": {
    "date-parts": [
      [
        2009,
        2,
        19
      ]
    ]
  },
  "reference": [
    {
      "key": "185_CR1",
      "doi-asserted-by": "publisher",
      "first-page": "353",
      "DOI": "10.1126/science.1072994",
      "volume": "297",
      "author": "J Hardy",
      "year": "2002",
      "unstructured": "Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002, 297: 353-356. 10.1126/science.1072994.",
      "journal-title": "Science"
    },
    {
      "key": "185_CR2",
      "first-page": "S11",
      "volume": "25",
      "author": "F Gervais",
      "year": "2004",
      "unstructured": "Gervais F: GAG mimetics: potential to modify underlying disease process in AD. Neurobiol Aging. 2004, 25: S11-12.",
      "journal-title": "Neurobiol Aging"
    },
    {
      "key": "185_CR3",
      "doi-asserted-by": "publisher",
      "first-page": "1757",
      "DOI": "10.1212/01.wnl.0000244346.08950.64",
      "volume": "67",
      "author": "PS Aisen",
      "year": "2006",
      "unstructured": "Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D: A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006, 67: 1757-1763. 10.1212/01.wnl.0000244346.08950.64.",
      "journal-title": "Neurology"
    },
    {
      "issue": "Suppl 16",
      "key": "185_CR4",
      "doi-asserted-by": "crossref",
      "first-page": "39",
      "DOI": "10.1017/S1092852900027061",
      "volume": "13",
      "author": "NR Relkin",
      "year": "2008",
      "unstructured": "Relkin NR: Current state of immunotherapy for Alzheimer's disease. CNS Spectr. 2008, 13 (Suppl 16): 39-41.",
      "journal-title": "CNS Spectr"
    },
    {
      "key": "185_CR5",
      "doi-asserted-by": "publisher",
      "first-page": "2264",
      "DOI": "10.1126/science.1067568",
      "volume": "295",
      "author": "RB DeMattos",
      "year": "2002",
      "unstructured": "DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM: Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002, 295: 2264-2267. 10.1126/science.1067568.",
      "journal-title": "Science"
    },
    {
      "key": "185_CR6",
      "doi-asserted-by": "publisher",
      "first-page": "1553",
      "DOI": "10.1212/01.WNL.0000159740.16984.3C",
      "volume": "64",
      "author": "S Gilman",
      "year": "2005",
      "unstructured": "Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64: 1553-1562. 10.1212/01.WNL.0000159740.16984.3C.",
      "journal-title": "Neurology"
    },
    {
      "key": "185_CR7",
      "doi-asserted-by": "publisher",
      "first-page": "735",
      "DOI": "10.2174/156652407783220741",
      "volume": "7",
      "author": "X Chen",
      "year": "2007",
      "unstructured": "Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD: RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med. 2007, 7: 735-742. 10.2174/156652407783220741.",
      "journal-title": "Curr Mol Med"
    },
    {
      "key": "185_CR8",
      "doi-asserted-by": "publisher",
      "first-page": "440",
      "DOI": "10.1172/JCI18162",
      "volume": "112",
      "author": "JL Eriksen",
      "year": "2003",
      "unstructured": "Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE: NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003, 112: 440-449.",
      "journal-title": "J Clin Invest"
    },
    {
      "key": "185_CR9",
      "doi-asserted-by": "publisher",
      "first-page": "483",
      "DOI": "10.1016/S1474-4422(08)70090-5",
      "volume": "7",
      "author": "GK Wilcock",
      "year": "2008",
      "unstructured": "Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA: Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008, 7: 483-493. 10.1016/S1474-4422(08)70090-5.",
      "journal-title": "Lancet Neurol"
    },
    {
      "key": "185_CR10",
      "doi-asserted-by": "publisher",
      "first-page": "1031",
      "DOI": "10.1001/archneur.65.8.1031",
      "volume": "65",
      "author": "AS Fleisher",
      "year": "2008",
      "unstructured": "Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJl: Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008, 65: 1031-1038. 10.1001/archneur.65.8.1031.",
      "journal-title": "Arch Neurol"
    },
    {
      "key": "185_CR11",
      "doi-asserted-by": "publisher",
      "first-page": "391",
      "DOI": "10.1016/j.nurt.2008.05.010",
      "volume": "5",
      "author": "MS Wolfe",
      "year": "2008",
      "unstructured": "Wolfe MS: Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics. 2008, 5: 391-398. 10.1016/j.nurt.2008.05.010.",
      "journal-title": "Neurotherapeutics"
    },
    {
      "key": "185_CR12",
      "doi-asserted-by": "publisher",
      "first-page": "399",
      "DOI": "10.1016/j.nurt.2008.05.007",
      "volume": "5",
      "author": "AK Ghosh",
      "year": "2008",
      "unstructured": "Ghosh AK, Gemma S, Tang J: beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics. 2008, 5: 399-408. 10.1016/j.nurt.2008.05.007.",
      "journal-title": "Neurotherapeutics"
    },
    {
      "key": "185_CR13",
      "doi-asserted-by": "publisher",
      "first-page": "18495",
      "DOI": "10.1074/jbc.M906994199",
      "volume": "275",
      "author": "J McLaurin",
      "year": "2000",
      "unstructured": "McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE: Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J Biol Chem. 2000, 275: 18495-18502. 10.1074/jbc.M906994199.",
      "journal-title": "J Biol Chem"
    },
    {
      "key": "185_CR14",
      "doi-asserted-by": "publisher",
      "first-page": "779",
      "DOI": "10.1016/S1474-4422(08)70167-4",
      "volume": "7",
      "author": "L Lannfelt",
      "year": "2008",
      "unstructured": "Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW: Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008, 7: 779-786. 10.1016/S1474-4422(08)70167-4.",
      "journal-title": "Lancet Neurol"
    },
    {
      "key": "185_CR15",
      "doi-asserted-by": "publisher",
      "first-page": "11213",
      "DOI": "10.1073/pnas.93.20.11213",
      "volume": "93",
      "author": "CM Wischik",
      "year": "1996",
      "unstructured": "Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA. 1996, 93: 11213-11218. 10.1073/pnas.93.20.11213.",
      "journal-title": "Proc Natl Acad Sci USA"
    },
    {
      "key": "185_CR16",
      "doi-asserted-by": "publisher",
      "first-page": "894",
      "DOI": "10.1038/nm0908-894",
      "volume": "14",
      "author": "T Gura",
      "year": "2008",
      "unstructured": "Gura T: Hope in Alzheimer's fight emerges from unexpected places. Nat Med. 2008, 14: 894-10.1038/nm0908-894.",
      "journal-title": "Nat Med"
    },
    {
      "key": "185_CR17",
      "doi-asserted-by": "publisher",
      "first-page": "353",
      "DOI": "10.1111/j.1527-3458.2005.tb00053.x",
      "volume": "11",
      "author": "I Gozes",
      "year": "2005",
      "unstructured": "Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L: NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005, 11: 353-368.",
      "journal-title": "CNS Drug Rev"
    },
    {
      "key": "185_CR18",
      "doi-asserted-by": "publisher",
      "first-page": "146",
      "DOI": "10.1124/jpet.107.130526",
      "volume": "325",
      "author": "Y Matsuoka",
      "year": "2008",
      "unstructured": "Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS: A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008, 325: 146-153. 10.1124/jpet.107.130526.",
      "journal-title": "J Pharmacol Exp Ther"
    },
    {
      "key": "185_CR19",
      "doi-asserted-by": "publisher",
      "first-page": "207",
      "DOI": "10.1016/S0140-6736(08)61074-0",
      "volume": "372",
      "author": "RS Doody",
      "year": "2008",
      "unstructured": "Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008, 372: 207-215. 10.1016/S0140-6736(08)61074-0.",
      "journal-title": "Lancet"
    }
  ],
  "container-title": "BMC Medicine",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "http://link.springer.com/content/pdf/10.1186/1741-7015-7-7.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/article/10.1186/1741-7015-7-7/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1186/1741-7015-7-7",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2017,
        6,
        18
      ]
    ],
    "date-time": "2017-06-18T13:12:08Z",
    "timestamp": 1497791528000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "http://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-7-7"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2009,
        2,
        19
      ]
    ]
  },
  "references-count": 19,
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2009,
          12
        ]
      ]
    }
  },
  "alternative-id": [
    "185"
  ],
  "URL": "http://dx.doi.org/10.1186/1741-7015-7-7",
  "relation": {},
  "ISSN": [
    "1741-7015"
  ],
  "subject": [],
  "container-title-short": "BMC Med",
  "published": {
    "date-parts": [
      [
        2009,
        2,
        19
      ]
    ]
  },
  "article-number": "7"
}